Monday, 18 Nov 2019

You are here

RheumNow Week in Review – 22 July 2016

Highlights from this week on RheumNow.com include:

  1. In Tofacitinib developmental trials in RA and Psoriasis, there were 1821 women of child-bearing age who were exposed; 47 became pregnant (33 monoRx). There were no deaths and one congenital malformation (1 Pulmonic valve stenosis), 7 Spontaneous Abortions. http://buff.ly/2azDHwd
  2. BMS has a new autoinjector for abatacept (ORENCIA) called "ClickJect" with a 15 sec delivery duration https://t.co/6QHIqK51Pj
  3. Between 10-50% of colorectal cancer patients have a positive ANA by either EIA or IIF. Small study but instructive. https://t.co/WWMbH3J4Vw
  4. Pirfenidone is FDA approved for IPF. Open label study 63 PSS patients with IPF show it tolerable and safe but no effect on outcomes https://t.co/j2ujvmfMnF
  5. NEJM article by Drs. Taurog & Colbert review ankylosing spondylitis & Spondyloarthritis. https://t.co/L6lQSi9Gyn
  6. RWCS Pearl: Dapsone can be of benefit in SCLE patients who do not respond to antimalarials. https://t.co/5cOXVH42Xi
  7. WEGENT compared outcomes in 112 GPA & MPA patients; Imuran & MTX had similar 10 yr survival, relapse rates, & toxicities https://t.co/dIl4wnsRzY
  8. Adherence to T2T in 198 early RA pts had no effect on Xrays or 12 mos DAS, but significantly improved DAS & functional outcomes at 3 yrs. https://t.co/XrXhnEkkUl
  9. MTX in Psoriatic arthritis achieves MDA – minimal disease activity criteria in <20%. MDA defined as 5 or more of the following 7 criteria: SJC, PASI, entheses≤1, BSA≤3%, HAQ≤0.5, pt global≤20, Pt pain≤15. https://t.co/dO6qyys8yy
  10. Epigenetic Changes to Inflammasome Found in Autoinflammatory Syndromes. 
  11. DEXA Still Needed While on Bisphosphonates: a study of 6629 Canadian women with osteoporosis taking bisphosphonates finds ~20% have decrease in bone density on medication
  12. Prevalence of Spondyloarthropathy in Fibromyalgia. Sacroiliitis found in 8% of 99 FM patients. Axial SpA found in 10%. Inflammatory MRI imaging changes found in 17% to 25% of patients. 
  13. Will Patent Extensions Delay Biosimilar Arrivals
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – ACR 2019 Round Up (11.15.19)

Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.

RheumNow Podcast – Better Ways to Treat Gout (11.8.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Ghastly, Ghoulish News (10.31.19)

Dr. Jack Cush reviews recent journal articles and info bits from the past week on RheumNow.com. 

RheumNow Podcast – The Shoes Maketh the Doctor (10.25.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Fight or Switching (DMARDs) (10.18.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.